Johnson & Johnson (JNJ) received an 88% rating from Validea's P/B Growth Investor model, based on Partha Mohanram's strategy, which identifies low book-to-market stocks with sustained future growth potential. As a large-cap growth stock in the Biotechnology & Drugs sector, JNJ's underlying fundamentals and valuation align strongly with this academically-derived growth model, passing most criteria despite failing the 'Research and Development to Assets' test. This 88% score indicates significant interest from the strategy, positioning JNJ favorably within a growth-oriented investment framework.
Johnson & Johnson (JNJ) has been identified as a strong candidate by Validea's P/B Growth Investor model, securing an 88% rating which signifies notable interest from the academically-derived strategy. This model, developed by Partha Mohanram, specifically targets low book-to-market stocks that exhibit fundamental signals of sustained future growth. As a large-cap in the Biotechnology & Drugs industry, JNJ successfully passed nearly all of the model's criteria, including key metrics such as Return on Assets, Cash Flow from Operations to Assets, and low variance in ROA and sales, indicating strong operational efficiency and stability. However, the analysis flagged a single weakness, with JNJ failing the 'Research and Development to Assets' test. This particular failure warrants attention, as R&D is a critical growth driver in its sector, even as the company's other financial health indicators are robust.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
